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Abstract
Aims/hypothesis The association between the mitochondrial
DNA 16181–16193 polycytosine variant (known as the
OriB variant as it maps to the OriB origin of replication)
and type 2 diabetes has not been reliably characterised, with
studies reporting conflicting results. We report a systematic
review of published literature in Europid populations, new
data from the Norfolk Diabetes Case–Control Study and a
meta-analysis to help quantify this association.
Methods We performed a systematic review identifying all
the studies of the OriB variant and type 2 diabetes in
Europid populations published before January 2013. We
typed the OriB variant by pyrosequencing and sequencing in
the Norfolk Diabetes Case–Control Study, which comprised
5,574 type 2 diabetes cases and 6,950 population-based
controls.
Results Overall, the meta-analysis included eight published
studies plus the current new results, with a total of 11,794
type 2 diabetes cases and 14,465 controls. In the Norfolk
Diabetes Case–Control Study, the OR for type 2 diabetes for
the OriB variant was 1.09 (95% CI 0.96, 1.24). In a com-
bined analysis, the relative risk for type 2 diabetes for the
OriB variant in Europid populations was 1.10 (95% CI 1.01,
1.20; p=0.03)
Conclusions/interpretation Results from this systematic re-
view and meta-analysis suggest that the mitochondrial DNA
OriB variant is modestly associated with an increased risk of
type 2 diabetes in Europid populations, with an effect size
comparable with that of recently identified variants from
genome-wide association studies.
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Recent genome-wide association studies (GWAS) have
identified many common variants in the nuclear genome
that are associated with type 2 diabetes [1–3]. However,
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the identified variants explain only a small proportion of the
heritability of type 2 diabetes. The unexplained heritability
could be due partly to interactions with environmental and
lifestyle factors, rare variants, epigenetic factors or possibly
mitochondrial DNA (mtDNA) variants. Mutations in
mtDNA such as the 3243A\G mutation in the mtDNA-
encoded tRNALeu(UUR) gene (also known as MTTL1) are
associated with maternally inherited diabetes. Even though
this mutation has a prevalence of 1 in 400, it causes fewer
than 2% of type 2 diabetes cases [4, 5]. As with many other
monogenic forms of diabetes, it is possible that extreme
functional mutations in mitochondrial DNA cause syndromic
forms of diabetes while less severe common variants are more
weakly associated with typical type 2 diabetes.
A common mtDNA variant that results in a T to C
substitution at the nucleotide position 16189 (also called
the 16189 variant) lies in the hypervariable D-loop region
of mtDNA for replication and transcription [6]. The mtDNA
16189 T>C transition frequently produces an uninterrupted
polycytosine (polyC) tract between nucleotide positions
16184 and 16193 that is susceptible to replication errors in
the important regulatory D-loop region. Because this variant
maps precisely to the OriB origin of replication, we re-
named it the ‘OriB variant’. In common with other homo-
polymeric C tracts in mtDNA [7], when the unbroken tract
exceeds 11 bp it generates heteroplasmic length variation.
As well as this alteration, the mtDNA becomes less suscep-
tible to DNase I, though this may be because of changes in
DNA secondary structure or protein binding [8].
The frequency of the OriB variant differs in ethnic
groups, with 10% in Europids, 30% in Asians, 50% in
Pima Indians and >95% in Polynesians; this distribution
has intriguing similarities with the prevalence of diabetes
[9]. The association of this variant with type 2 diabetes has
been studied previously, with apparently conflicting results
[8–27]. A previous review of four studies with a total of
1,455 type 2 diabetes cases and 3,132 controls reported that
the OriB variant was not associated with type 2 diabetes in
European populations [18]. However, most of those data
were from relatively small studies and although the meta-
analysis was able to exclude a very strong association in
European populations, it could not exclude the possibility
that the variant was modestly associated. A modest associ-
ation can only be detected by large, well-powered studies.
Our reassessment of the association of the OriB variant
with type 2 diabetes used the following approach to maxi-
mise power and minimise bias: (1) we investigated the
association between the OriB variant and type 2 diabetes
in a large European population (the Norfolk Diabetes Case–
Control Study), which included 5,574 type 2 diabetes cases
and 6,950 healthy controls; and (2) we conducted a meta-
analysis of studies of the OriB variant with type 2 diabetes
in Europid populations (e.g. European continental ancestry),
involving a total of 11,794 type 2 diabetes cases and 14,465
controls, over five time as many participants as in the
previous review [18].
Methods
Norfolk Diabetes Case–Control Study The Norfolk Diabetes
Case–Control Study is a study of men and women with type
2 diabetes in Norfolk. All type 2 diabetes patients identified
through general practice diabetes registers in Norfolk and
local hospital diabetes clinic and retinal screening
programme patient registers were invited to participate. A
total of 5,574 cases reporting British, Irish and/or other
white ethnic origin were included in the current analyses.
Other forms of diabetes were excluded by restricting cases
to those without insulin use during the first year of diagno-
sis, and those without cystic fibrosis, chronic pancreatitis or
long-term steroid use. A total of 6,950 controls free of
known diabetes at baseline or during follow-up were ran-
domly selected from European Prospective Investigation of
Cancer (EPIC)-Norfolk participants. Diabetes was excluded
in controls based on self-report (self-reported history of
diabetes, doctor-diagnosed diabetes and/or use of glucose-
lowering drugs), linkage to primary care registers, second-
ary care registers, hospital admissions and mortality data.
The Norfolk study was approved by the Norwich Local
Research Ethics Committee and written informed consent
was obtained from all participants.
Detection of the OriB variant We characterised the OriB
variant using initial Sanger cycle sequencing in 92 cases and
92 controls in the Norfolk study using Seq2 and Seq5 PCR
primers as previously described [28], but extended to in-
clude 21 M13/M13 Rev sequences. The primers were sup-
plied by IDT (Leuven, Belgium), PCR reagents by Qiagen
(Crawley, UK) and sequencing primers, reagents and equip-
ment by Applied Biosystems (Warrington, UK). The
population-specific variation was then used to develop a
pyrosequencing assay based on the method previously de-
scribed [29]. Primers were supplied by IDT, Streptavidin
Sepharose High Performance beads were from GE
Healthcare Life Sciences (Little Chalfont, UK) and all other
reagents and equipment were from Qiagen.
The same individuals selected for the initial Sanger cycle
sequencing were sequenced with the pyrosequencing assay.
The sequencing calls for the OriB region obtained by Sanger
cycle sequencing and pyrosequencing were 100% concor-
dant in these samples.
Following the successful validation of the pyrosequencing
assay, we used this method to screen the OriB region in
Norfolk Diabetes Case–Control Study participants, blinded
to case and control status, using 10 ng purified genomic
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DNA; 248 of these individuals were run in duplicate. For
samples with a homopolymeric C-tract sequence <10 we
had a concordance of 97.8% and for the homopolymeric C-
tract sequence ≥10 a concordance of <95%was achieved. The
difficulty in determining the precise number of Cs in the
homopolymeric C tract from PCR templates because of the
loss of linearity in long homopolymeric sequences and
heteroplasmic tract inflation has been previously discussed
[29]. In order to resolve the low level of sequence concor-
dance we repeated the sequence verification using the Sanger
cycle sequencing method for all 1,252 individuals with a
homopolymeric C-tract sequence ≥10. Again, we were unable
to get precise resolution of the homopolymeric C tract.
However, we were able to categorise these into four groups
by discriminating the polyT sequence prior to the homopoly-
meric C tract as previously described [29]. When grouped
together into all individuals with homopolymeric C tract ≥10,
concordance of 100%was achieved. Samples for a further 392
individuals failed with the initial pyrosequencing reaction and
27 samples were uncategorised using pyrosequencing. All
these samples were re-sequenced by Sanger cycle sequencing.
The final call rate for the 12,795 was 99% and the concor-
dance of the sequence in the duplicate samples was 98.3%.
Major haplogroups for the 16189 variant were also estimated
based on European mtDNA haplogroups and haplogroups
previously constructed for the UK population [15].
Literature search and data extraction We sought to identify
all studies published until 9 January 2013 describing the
association of the OriB variant with type 2 diabetes in
Europid populations. We also undertook a separate analysis
in Asians. Articles were identified through electronic searches
of MEDLINE and the Chinese National Knowledge
Infrastructure Database by scanning the reference lists of
articles identified for all relevant studies and review articles
(including meta-analyses), and by correspondence with the
lead authors of included studies. PRISMA guidelines were
followed. Electronic literature searches combined search
terms related to the OriB variant (mitochondrial DNA or
mtDNA or mt DNA or mitochondrial polymorphism or
polycytosine tract or polyC tract) and diabetes (diabetes or
glucose or metabolic syndrome or hyperglycaemia) without
language restriction (Fig. 1). The following data were
extracted from each study according to a fixed protocol: study
design; geographical location; ethnic group of participants;
number of cases and controls; genotyping methods; and mean
age of type 2 diabetes cases (electronic supplementary material
[ESM] Table 1).
Statistical analysis The association between the OriB vari-
ant and type 2 diabetes in the Norfolk Diabetes Case–
Control Study was tested using logistic regression models
adjusted for age, sex and body mass index. Summary ORs
for type 2 diabetes and the OriB variant were calculated
using a random-effects model that included between-study
heterogeneity. Consistency of findings across studies was
assessed using the I2 statistic [30]. Heterogeneity was
assessed by using the Q statistic [31]. Publication bias was
assessed using funnel plots and the Egger test [32]. All
analyses were performed using Stata Statistical Software,
Release 11 (StataCorp LP, College Station, TX, USA). All
statistical tests were two-sided, with a significance level of
p<0.05, except where indicated.
Results
Norfolk Diabetes Case–Control Study The characteristics of
participants in the Norfolk Diabetes Case–Control Study are
described in Table 1. The mean age was 60.7 (SD 11.4)
years in cases and 59.3 (SD 9.3) years in controls. Women
comprised 41% of cases and 51.8% of the control popula-
tion. BMI was higher in the diabetes patients than in con-
trols and a greater proportion of the cases than controls
reported having a family history of diabetes. The frequency
5,519 potentially relevant articles 
identified by 9 January 2013
46 full-text articles retrieved 
for more detailed evaluation
5,423 excluded on basis of title 
Reviews:                          1,795 
Case reports: 454
In vitro studies:                 92
Other inappropriate:         3,082
50 excluded on basis of abstract
No relevant mitochondrial 
information (e.g. different 
variants and mutations)         37
Inappropriate population:       4
Other inappropriate:               9 
19 potentially relevant articles 
included in the meta-analysis
27 articles excluded owing to no 
relevant mitochondrial data; family 
studies; duplicate publications
9 studies in Europid populations
11 studies in Asian populations     
Norfolk Diabetes Case–Control
Study 
Fig. 1 Flow diagram of studies identified in the literature search for
the association between the OriB variant and the risk of type 2 diabetes
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of the OriB variant in the NorfolkDiabetes Case–Control Study
is summarised in ESM Table 2. The frequency of the OriB
variant was higher in the type 2 diabetes cases (579 of 5,574,
10.4%) than in controls (675 of 6,950, 9.7%). Individuals with
this variant are mainly within four haplogroups: H, T, U and X.
Overall, 12.1% of individuals were categorised as ‘other vari-
ants’, which comprised 21 different variants. From these 21
different variants, we have identified six new variants (variants
16–21) that have not been previously reported. Individuals
within other variants are mainly within three haplogroups: H,
T and U. Within the other variants, the most common one
(variant 15) is within the T haplogroup (ESM Table 2). The
OriB variant was not significantly associated with type 2 dia-
betes (OR 1.09; 95% CI 0.96, 1.24; p=0.20) (ESM Table 3).
There was no interaction between the OriB variant and BMI for
type 2 diabetes risk (OR 1.00; 95% CI 0.99, 1.02; p=0.28).
Systematic review and meta-analysis We identified 5,519
articles from literature searches (Fig. 1). After exclusions
[8, 12, 14, 17, 19–23, 25, 26, 33–36], eight studies in
Europid populations were included. For other ethnic groups,
we identified 11 studies in Asian populations; genotype
frequencies were unavailable in one Asian population study
[33], which was excluded for meta-analysis. A further three
studies were excluded because the data duplicated or
overlapped with reports already included in the review
[34–36]. Our meta-analysis included eight genetic associa-
tion studies in Europid populations plus the new data from
the Norfolk Diabetes Case–Control Study, giving a total of
11,794 type 2 diabetes cases and 14,465 controls. Eleven
studies in Asian populations included a total of 4,691 type 2
diabetes cases and 3,530 controls. Three studies used
sequencing/pyrosequencing methods to identify the OriB
variant and the remaining studies used PCR/RFLP and
sequencing (ESM Table 1).
There was little evidence of heterogeneity between the
nine Europid population studies (I2=0%; 95% CI 0%, 65%;
p=0.68). Overall, the summary OR for type 2 diabetes risk
for the OriB variant in Europid populations was 1.10 (95%
CI 1.01, 1.20; p=0.03; Fig. 2). When we excluded one study
that typed 16189 variant without probing tract homogeneity
[24], the summary OR for type 2 diabetes risk for the OriB
variant in Europid populations was 1.13 (95% CI 1.02, 1.25;
p=0.02). A funnel plot (not shown) did not indicate the
presence of publication bias in these studies (Begg’s test,
p=0.40). There was evidence of a moderate degree of het-
erogeneity between the 11 Asian studies (I2=41%; 95% CI
0%, 71%; p=0.08). The summary OR for type 2 diabetes
risk for the OriB variant in the Asian population was 1.49
(95% CI 1.27, 1.74; p=6.4×10−7) (ESM Fig. 1).
Discussion
Previous genetic studies and earlier meta-analyses of the
OriB variant have been dominated by small studies that
are susceptible to various forms of bias. A previous meta-
analysis concluded that the OriB variant was not associated
with type 2 diabetes in the European population, but it did
not include sufficient numbers of cases or controls to exclude
a modest association of this variant with diabetes [18].
Methods used by other studies were not specific for the
homopolymeric tract and hence underestimated the magnitude
of the association [24]. Given the absence of large individual
studies in Europid populations, we have conducted an updated
systematic review and meta-analysis of new and published
data, involving a total of 11,794 type 2 diabetes cases and
14,465 controls, which provides the most comprehensive
assessment to date of the association of the OriB variant with
type 2 diabetes in Europid populations. Our new data include
the single largest study so far, the Norfolk Diabetes Case–
Control Study, with a total of 5,574 type 2 diabetes cases
and 6,950 controls. Our meta-analysis suggests that there is
a statistically significant association of modest effect size
between the OriB variant and the risk of type 2 diabetes in
Europid populations. Our findings also suggest that the
magnitude of the association may vary by ethnic back-
ground. The magnitude of the measure of association is
comparable with that seen for variants identified by GWAS
and associated with type 2 diabetes. The level of signifi-
cance in this study is not as low as that seen in GWAS, but
this is a function of the much smaller sample size, which,
in itself, is a reflection of the much greater technical
difficulty of typing the OriB variant. The accepted GWAS
statistical thresholds for limiting false-positive associations
do not apply to this study as only the OriB variant has
been typed and this is not a genome-wide analysis. On the
basis of the magnitude of the association and its overall
statistical significance in Europid populations, the associa-
tion of the OriB variant with type 2 diabetes deserves
further investigation in additional case–control studies,
including in other ethnic groups where the higher fre-
quency of the OriB variant should increase the power to
detect a true association.
Table 1 Baseline characteristics of participants of the Norfolk
Diabetes Case–Control Study
Characteristic Type 2 diabetes cases Controls
N 5,574 6,950
Age (years)a 60.7 (11.4) 59.3 (9.3)
Women (%) 41.0 51.8
BMI (kg/m2)a 30.1 (5.7) 26.2 (3.8)
Family history of diabetes (%) 23.3 13.4
aMean (SD)
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Replication and transcription of mtDNA is complex,
being mediated by nuclear-encoded proteins. The mecha-
nisms of human mtDNA replication are far from resolved,
and several origins of replication have been proposed. One
of them, OriB, maps near one end of the major non-coding
region (NCR) of mammalian mtDNA [37]. Many molecules
of mtDNA contain a triple strand or D-loop region, and
OriB is located close to the 3′ end of a D-loop. The D-
loop may act as a platform for recruiting essential compo-
nents of the replisome to mtDNA, such as the β subunit of
the mitochondrial γ polymerase [38]. Therefore, the D-loop
might regulate recruitment of replication initiation factors to
OriB. Nevertheless, current understanding of the physiolog-
ical roles of the various mtDNA origins is limited and
nothing is known about the role of OriB in mtDNA replication
in the beta cell [37, 39]. OriB appears to be more important in
mtDNA replication during recovery from transient mtDNA
depletion than in mtDNA replication required for maintaining
appropriate mtDNA during cell doubling in culture. The
mtDNA content of blood cells is slightly lower in healthy
individuals with the OriB variant than in those with wild type,
suggesting that sequence variants might influence this origin’s
activity [40]. Furthermore, the sequence appears to influence
the access of proteins to this region. For instance, the variant
both restricts the DNase I footprint in the region [9] and
reduces the binding of the mitochondrial single-strand DNA
binding protein (mtSSB) [37]. These results suggest that the
OriB variant may alter protein binding in the NCR and thereby
affect mtDNA replication. Thus, our findings in the present
meta-analysis should stimulate further investigation of the
functional abnormalities underlying our observation, in par-
ticular the role of OriB and the homopolymeric C tract in the
aetiology of type 2 diabetes.
Given that the prevalence of the OriB variant is about
10% in Europid populations, the small increase (10%) in
diabetes risk associated with it would explain only a small
proportion of people with type 2 diabetes. However, given
that the prevalence of the variant is higher in Asian
populations and that the magnitude of association with
diabetes is also greater, it is possible that the population-
attributable fraction related to this variant could differ mark-
edly by ethnic group. Hence, it might explain an important
component of variance in the worldwide distribution of
diabetes [9]. It has also been proposed that the association
of the OriB variant with diabetes might be stronger in
certain subgroups, such as those with obesity [17]. Our
analysis of the Norfolk Diabetes Case–Control Study does
not provide support for the existence of such interactions
with BMI or other characteristics. As our meta-analysis was
based on published results and not individual participant data,
we were unable to explore interactions by participant-level
characteristics in the meta-analysis.
The strengths and limitations of the current study merit
consideration. Our meta-analysis involved five times more
data than the earlier review. These data provided greater
power than previously available to quantify the magnitude
of association. Although we have also identified a large
effect of the OriB variant and type 2 diabetes in Asian
populations, the sample sizes in the majority of studies in
Asian populations were very small. Meta-analysis of these
smaller studies is more likely to overestimate such associa-
tions and lead to biased results. There was evidence of
heterogeneity identified between Europids and Asians
(I2=45%; 95% CI 7%, 71%; p=0.02). Therefore, in this
report, we focused on the association of the OriB variant
and type 2 diabetes in Europid populations, which could
Poulton et al (2002) [11] 
Gill-Randal et al (2001) [10] 
Crispim et al (2006) [13] 
Poulton et al (2002) [15] 
Mueller et al (2011) [27] 
Mohlke et al (2005) [16] 
Chinnery et al (2005) [18] 













0.2 0.5 1.0 1.5 2.5 4.0 6.0
1.10   (1.01,1.20) 
Authors/study [ref.] Cases/controls OR and 95% CI Fig. 2 The association of the
mtDNA OriB variant with
type 2 diabetes in Europid
populations
Diabetologia (2013) 56:1907–1913 1911
give us more reliable results. In contrast to earlier studies
that used PCR/RFLP and sequencing methods, we made use
of a combination of pyrosequencing and Sanger sequencing
methods to accurately genotype over 12,000 individuals for
the OriB variant in the Norfolk Diabetes Case–Control
Study, which should be less liable to misclassification bias
in the OriB variant. Although the Norfolk study is the single
largest study so far, it is still insufficient alone to enable
reliable assessment of the moderate association between the
OriB variant and the risk of type 2 diabetes in Europid
populations. However, in a meta-analysis of this and other
published studies, we were able to demonstrate a modest
association. It is possible that studies that did not accurately
identify the variations around the homopolymeric tract could
have underestimated its effect [24]. Because we did not have
access to individual data in the published studies, we could not
control for population stratification, adjust for possible
confounding factors, explore heterogeneity by individual-
level characteristics or perform haplogroup analyses.
In summary, this meta-analysis of new and previously
published data suggests that the mitochondrial DNA OriB
variant is modestly associated with an increased risk of type
2 diabetes in Europid populations. Further studies to inves-
tigate the functional abnormalities underlying this associa-
tion are required, as are additional epidemiological investi-
gations of ethnic group differences.
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